+

WO2005056766A3 - Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 - Google Patents

Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 Download PDF

Info

Publication number
WO2005056766A3
WO2005056766A3 PCT/US2004/041020 US2004041020W WO2005056766A3 WO 2005056766 A3 WO2005056766 A3 WO 2005056766A3 US 2004041020 W US2004041020 W US 2004041020W WO 2005056766 A3 WO2005056766 A3 WO 2005056766A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha2
therapeutic
composition
hyperproliferative
nucleic acid
Prior art date
Application number
PCT/US2004/041020
Other languages
English (en)
Other versions
WO2005056766A2 (fr
Inventor
Michael S Kinch
Original Assignee
Medimmune Inc
Michael S Kinch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/004,794 external-priority patent/US20050153923A1/en
Priority claimed from US11/004,795 external-priority patent/US20050147593A1/en
Application filed by Medimmune Inc, Michael S Kinch filed Critical Medimmune Inc
Publication of WO2005056766A2 publication Critical patent/WO2005056766A2/fr
Publication of WO2005056766A3 publication Critical patent/WO2005056766A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés et des compositions destinés au traitement, à la gestion ou à la prévention d'une maladie cellulaire hyperproliférative, notamment du cancer. Les procédés selon l'invention consistent à administrer une quantité efficace d'une composition ciblant des cellules exprimant une tyrosine kinase réceptrice de la famille Eph, telle que EphA2 ou EphA4, pour le traitement, la gestion ou la prévention de maladies hyperprolifératives, notamment du cancer. Dans un mode de réalisation, le procédé selon l'invention consiste à administrer à un sujet une composition contenant un groupe fonctionnel liant EphA2 ou EphA4, attaché à un véhicule d'administration, et un ou plusieurs agents thérapeutiques ou prophylactiques traitant ou prévenant une maladie hyperproliférative, associés au véhicule d'administration. Dans un autre mode de réalisation, le procédé selon l'invention consiste à administrer à un sujet une composition contenant un acide nucléique présentant une séquence nucléotidique codant un groupe fonctionnel liant EphA2 ou EphA4, et un agent thérapeutique ou prophylactique traitant ou prévenant une maladie hyperproliférative. Dans un autre mode de réalisation, le procédé selon l'invention consiste à administrer à un sujet une composition contenant un groupe fonctionnel liant EphA2 ou EphA4, et un acide nucléique présentant une séquence nucléotidique codant un agent traitant ou prévenant une maladie hyperproliférative, associé au véhicule d'administration. L'invention concerne également des compositions pharmaceutiques.
PCT/US2004/041020 2003-12-04 2004-12-06 Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4 WO2005056766A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US52739603P 2003-12-04 2003-12-04
US60/527,396 2003-12-04
US11/004,794 US20050153923A1 (en) 2003-12-04 2004-12-03 Targeted drug delivery using EphA2 or EphA4 binding moieties
US11/004,794 2004-12-03
US11/004,795 2004-12-03
US11/004,795 US20050147593A1 (en) 2003-05-22 2004-12-03 EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders

Publications (2)

Publication Number Publication Date
WO2005056766A2 WO2005056766A2 (fr) 2005-06-23
WO2005056766A3 true WO2005056766A3 (fr) 2008-01-31

Family

ID=34682013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041020 WO2005056766A2 (fr) 2003-12-04 2004-12-06 Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4

Country Status (1)

Country Link
WO (1) WO2005056766A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
WO2003099313A1 (fr) 2002-05-23 2003-12-04 Purdue Research Foundation Tyrosine phosphatase de faible poids moleculaire (lmw-ptp) servant de cible a usage diagnostique et therapeutique
EP1617864A4 (fr) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 et troubles cellulaires hyperproliferatifs non-neoplastiques
JP2006523240A (ja) * 2003-04-11 2006-10-12 メディミューン，インコーポレーテッド ＥｐｈＡ２、低増殖性細胞障害ならびに上皮および内皮の再構成
EP1638514A4 (fr) * 2003-06-06 2009-11-18 Medimmune Inc Utilisation du epha4 et de ses modulateurs, pour le diagnostic, le traitement et la prevention du cancer
CA2546763A1 (fr) * 2003-11-20 2005-06-09 Medimmune, Inc. Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
WO2006026820A1 (fr) * 2004-09-08 2006-03-16 The University Of Queensland Methode de traitement et agents utiles pour celle-ci
WO2007103522A2 (fr) * 2006-03-08 2007-09-13 Wake Forest University Health Sciences Éphrine-a1 monomère soluble
EP1914242A1 (fr) * 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
SI2134374T1 (sl) 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
EP2542696B1 (fr) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarqueurs pour théranostique
AU2011237669B2 (en) 2010-04-06 2016-09-08 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BRANTLEY ET AL.: "Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo", ONCOGENE, vol. 21, 2002, pages 7011 - 7026 *
CARLES-KINCH ET AL.: "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior", CANCER RESEARCH, vol. 62, May 2002 (2002-05-01), pages 2840 - 2847 *
CHENG ET AL.: "Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors", NEOPLASIA, vol. 5, no. 5, 2003, pages 445 - 456 *
CHENG ET AL.: "The Ephrins and Eph receptors in angiogenesis", CYTOKINE & GROWTH FACTOR REVIEWS, vol. 13, 2002, pages 75 - 85 *
CROSASSO ET AL.: "Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs", J. OF PHARMACEUTICAL SCIENCES, vol. 86, no. 7, July 1997 (1997-07-01), pages 832 - 839 *
EASTY ET AL.: "Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma", INT. J. CANCER, vol. 71, 1997, pages 1061 - 1065 *
KOOLPE ET AL.: "An ephrin mimetic peptide that selectively targets the EphA2 receptor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 49, 2002, pages 46974 - 46979 *
MERIC ET AL.: "Expression profile of tyrosine kinases in breast cancer", CLINICAL CANCER RESEARCH, vol. 8, 2002, pages 361 - 367 *
OGAWA ET AL.: "The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization", ONCOGENE, vol. 19, 2000, pages 6043 - 6052 *
ZELINSKI ET AL.: "EphA2 overexpression causes tumorigenesis of mammary epithelial cells", CANCER RESEARCH, vol. 61, 2001, pages 2301 - 2306 *

Also Published As

Publication number Publication date
WO2005056766A2 (fr) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2005055948A3 (fr) Epha2, epha4 et lmw-ptp et procedes de traitement de maladies cellulaires hyperproliferatives
WO2006113623A3 (fr) Elimination d'une population de cellules heterogenes ou mixtes dans des tumeurs
WO2004111192A3 (fr) Liberation ciblee sur des cellules exprimant la legumaine
WO2004105782A3 (fr) Systeme de liberation de medicament ciblee sur une tumeur et utilisations associees
WO2005056766A3 (fr) Administration ciblee de medicaments au moyen de groupes fonctionnels liant epha2 ou epha4
US9080173B2 (en) Methods and compositions for RNAi-based cancer treatment
WO2006123248A3 (fr) Ameliorations apportees a des methodes et a des dispositifs destines a l'administration de produits therapeutiques a la sphere oculaire d'un patient
WO2007143316A3 (fr) Composés et procédés de modulation de l'expression de sglt2
WO2008091375A3 (fr) Salmonella atténuée en tant que système de distribution pour une thérapie de tumeur à base d'arnsi
MX2009002893A (es) Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
WO2007008463A3 (fr) Polytherapie associant un anticorps anti-ctla-4 et un oligodesoxynucleotide synthetique a motif cpg destinee au traitement du cancer
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2007118245A3 (fr) Procedes et compositions portant sur des particules de phage de virus adenoassocie
WO2006138608A3 (fr) Compositions pharmaceutiques et leur utilisation
NO20061319L (no) 5-arylpyrimidiner som anticancer legemidler
WO2006039704A3 (fr) Composition pharmaceutique et methode de traitement d'une arthropathie a capsule articulaire
WO2007078443A3 (fr) Methodes visant a traiter une maladie a l'aide de copolymeres aleatoires
WO2008097927A3 (fr) Traitement et prévention de maladies neurodégénératives utilisant la thérapie génétique
WO2005051297A3 (fr) Therapie utilisant une association de medicaments pour traiter l'obesite
WO2008109432A3 (fr) Ciblage thérapeutique des interleukines utilisant l'arnsi dans des liposomes neutres
WO2004043378A3 (fr) Procedes et compositions utilisant des medicaments d'inhibition selective de cytokine pour traiter et maitriser des cancers et d'autres maladies
WO2006115770A3 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
WO2005009394A3 (fr) Administration de medicaments dans le systeme nerveux
WO2005115360A3 (fr) Formulations de substances analgesiques et leurs methodes d'administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载